Nov 16, 2020 7:00am EST Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates
Nov 12, 2020 4:31pm EST Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit
Nov 9, 2020 4:15pm EST Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit
Nov 9, 2020 8:30am EST Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
Oct 15, 2020 7:00am EDT Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
Sep 29, 2020 4:05pm EDT Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis
Sep 28, 2020 4:15pm EDT Tonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine Programs
Sep 17, 2020 9:17am EDT Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?
